Practical guidance for the management of aromatase inhibitor-associated bone loss

Keyphrases

• Aromatase Inhibitor Therapy 100%
• Practical Guidance 100%
• Aromatase Inhibitor-associated Bone Loss 100%
• Women with Breast Cancer 75%
• Risk Factors 37%
• Bone Loss 37%
• T-score 37%
• Fracture Risk Factors 37%
• Fracture Risk 37%
• Zoledronic Acid 25%
• Bone Mineral Density 25%
• Postmenopausal Women 12%
• Clinical Evidence 12%
• Age-matched 12%
• Bisphosphonate Therapy 12%
• Low Body Mass Index 12%
• Randomized Clinical Trial 12%
• Clinically Significant 12%
• Clinical Practice Guidelines 12%
• Treatment Recommendations 12%
• Population-based 12%
• Changes in Risk 12%
• High-risk Women 12%
• Evidence Support 12%
• Evidence-based Medicine 12%
• Current Treatment 12%
• Meeting Abstracts 12%
• Vitamin D Supplementation 12%
• Pertinent Information 12%
• Risk Status 12%
• Prospective Clinical Trial 12%
• Bisphosphonate Treatment 12%
• Low BMI 12%
• Osteopenia 12%
• Incremental Risk 12%

Pharmacology, Toxicology and Pharmaceutical Science

• Aromatase Inhibitor 100%
• Breast Cancer 60%
• Zoledronic Acid 20%
• Bisphosphonic Acid Derivative 20%
• Clinical Trial 10%
• Randomized Clinical Trial 10%
• Vitamin D 10%

Nursing and Health Professions

• Breast Cancer 60%
• Bone Density 20%
• Bisphosphonic Acid Derivative 20%
• Zoledronic Acid 20%
• Practice Guideline 10%
• Body Mass 10%
• Vitamin D 10%
• Systematic Review 10%